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Research with neural tissue in 3D is receiving great attention recently, since 3D offers a more physiological setting
than traditional 2D cultures. In this commentary we overview and compare cerebral organoids and other 3D
aggregated cell cultures. Last we briefly summarize examples of neurological diseases, mostly neurodevelopmental,
where organoids are starting to be of help to understand the disease etiology, and in some cases to design therapies.
In vitro studies of neural tissue development, physiology, biochemistry, and molecular and cell biology are
presently understood to be more relevant if experimental procedures are conducted in 3D as compared with
2D (monolayer cultures). The rationale behind this notion resides in the mutual interaction of cells in 3D, the
possibility for the cells/tissue to generate its own extracellular matrix, and the cells’ capacity to establish 3D
projections and multiple interactions, and that this would yield tissue constructs and organoids that better resemble
the in vivo developmental processes, and the organization of functional, mature tissues, as well as the physiology
and pathophysiology of neurodevelopmental processes, possibly including aging.
The 3D human neural tissue culture dates back to decades ago, early 1990s, when Weiss and collaborators
described the generation of human neurospheres (spheroids), comprised of human neural stem cells, co-existing with
differentiated cells [1]. The neurosphere culture method rapidly expanded and was extensively used, until presently.
Interestingly, by that time and for many years, the focus was on how to proliferate the recently identified neural
stem cells, rather than on the cytoarchitecture of the (putatively) self-organizing neural tissues in neurospheres. As
a matter of interest, at that time the term ‘neural stem’ was not even widely accepted and therefore it was important
to demonstrate their successful proliferation in culture. Consequently, neurosphere cultures were rendered as an
experimental tool to proliferate the few neural stem cells that remained in such stem cell stage. Later on, the
capacity to generate neurospheres, was used in clonogenic assays, to identify neural stem cells in a given neural
cell preparation. But little, if any, attention was paid to the 3D organization of developing neural tissue in the 3D
neurospheres.
With the availability of pluripotent stem cells (PSCs) by the end of the 90s, a renewed interest in 3D cultures
arose. The trigger for this revival was the PSCs’ characteristic of pluripotency (understood as the capacity to give rise
to cell derivatives of different embryonic germinal layers, that is, endoderm, mesoderm and ectoderm). The new
angle was to let the cells develop into different tissues, after providing them with the appropriate developmental
signals. Subsequently, during the last decade, different groups managed the development of organ-like tissues in 3D
cultures of PSCs, that resembled some of the histological features, tissue architecture and some basic functionality
of their in vivo counterparts (e.g., intestine, retina, cerebral cortex, . . . ; [2–5]).
More recently, we have seen an exponential rise of published studies using 3D human neural cell cultures,
ranging from simple cell aggregates (lacking tissue cytoarchitecture, cellular self-organization), to other rather
organized tissues generated from embryoid bodies. It is important to highlight at this point that organoids are
much more complex than simple 3D aggregates of cells. An organoid is generated through a series of complex
developmental decisions and continuous processes, combined with a progressive restriction of proliferation of the
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progenitors responsible for the generation of such organ-like structure. Therefore, the successful in vitro organ-like
development is the result of a highly complex-combinatorial, time-restricted contribution of signals and events. In
other words, it is the re-action of the developing tissue to the provided cues, resulting into decreased proliferation
while simultaneously and progressively integrating developmental signals, which prompt migration, differentiation
and maturation that together render an organ-like histological structure. All of these processes are similar to the
events during embryonic development in vivo. The 3D cellular aggregates, on the other hand, are more simple to
generate and less likely to integrate any development signals or to show cellular self-organization. However, they
constitute good models for the quick assessment of cell biology in 3D (see an example on Alzheimer’s disease,
below).
This is what we can conclude from our own work with both types of 3D tissues (Supplementary Figure 1),
where we have compared 3D cell aggregates with real cerebral organoids, finding that their properties are essentially
different, and therefore, their potential uses become different. In brief, real organoids recapitulate development and
maturation, possibly aging, and are therefore useful to study biological processes related to these events, whereas
3D aggregates provide simple means to evaluate very basic questions in 3D, like neuron generation or neuron/glia
differentiation and survival, constituting a good instrumental tool, but not recapitulating nerve tissue development.
Once the difference between cell aggregates and organoids has been discussed, we will explore the potential that
the currently available cerebral organoid models offer for the investigation of neurological diseases, deficits, and
also for basic neurobiology research.
Origins of the cerebral organoid technology
After seminal studies by the groups of Sasai, Clevers, Knoblich and Pasca [2–5], the available technical knowledge was
coaxed into published procedures for the generation of differentiated neural/neuronal clusters or neuronal regions
in 3D in cerebral organoids [5–7]. These 3D tissue constructs showed some regions containing neural tissue with a
cytoarchitecture reminiscent of their in vivo counterparts (mostly cortical tissue, since this is the default phenotype
according to those protocols). Therefore, those 3D tissues were described as ‘cerebral organoids’ or ‘cerebroids’
(colloquially referred to as ‘mini-brains’). However, the term mini-brain is profoundly misleading, since these 3D
tissues do not organize themselves into discrete regions showing interconnections resembling the developing brain.
When examining the histology of the cerebral organoids in detail, the outcome was on the one hand new and
exciting, thus promising. But on the other hand, it became clear that the current cerebroids have limitations and
there still remain many challenges to overcome before having a real human brain model. Multiple reports described
the appearance of neuralized tissue, with some cellular organization, but the whole composition of such 3D tissue
constructs did not resemble or was not reminiscent of a developing brain. In contrast, the appearance of discrete,
regionally specified brain regionswas very limited, and subjected to a stochastic process. In some organoids there were
neural tissues, while in others the neural tissue did not appear. In some successful, neuralized, cerebral organoids,
some markers of regionally specified neurons appeared, randomly and without control by the investigator. In some
cases, groups of cells expressing cortical or hypothalamic neurons appeared, while in many other cases those regions
did not appear [2,5,7,8]. This scenario calls for a better engineering by the experts. Engineers collaborating with
biologists. Recently, a simple scaffolding procedure (randomly arranged, floating poly(lactide-co-glycolide) fibers
to which the embryoid bodies attached) has been described, partially enhancing the reproducibility of generating
successful cerebroids containing cortex-like tissue from human PSCs [8].
Essentially, we are at a very initial stage in the research process to decipher how to generate cerebral organoids
really recapitulating the development of the human brain. For this challenging task, it is obvious that some type of
scaffolding, providing regional and time-resolved developmental cues, physical support, together with an artificial
or biological vascularization/perfusion, is needed. For some applications, the external provision of microglial cells
will definitely be a must, when dealing with physiopathological processes mediated by microglia. It is unclear at the
moment how to combine different cell types during the generation of successfully developing cerebral organoids.
After recognizing the exceptional research opportunities that cerebroids offer, since they recapitulate the gen-
eration of some histologically organized brain tissue, we need to adopt a critical approach. Presently, a cerebral
organoid is an almost spherical structure (isotropic, no orientation landmarks, no polarization or developmental
axis), where different regions develop/appear randomly, with no recognizable (brain) organ-like patterns, showing
only discrete regions resembling parts of the in vivo brain organ.
Initial attempts to provide the cerebroids with some kind of regional patterning have been reported (e.g., for
midbrain, forebrain or hypothalamic identity [9–11]; or striatal and cortical [12]). Currently used procedures for
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cerebroid generation use culture media and inductive/differentiation/maturation cocktails optimized for their
default differentiation toward the generation of cortical tissue. The studies aiming at generating other brain
identities used procedures originally developed in 2D tissue culture to provide the cells with the appropriate,
chronologically ordered, development cues, applied to the cells in the form of soluble factors/morphogens dissolved
in the culture medium. These studies described a ‘bulk’ patterning, bathing the developing organoids with cocktails
that thus convert the whole structure into, for example, hypothalamic or midbrain identity. This approach resulted
in a tissue construct that did not recapitulate neither brain organ development, nor the brain circuitry. Regional
induction existed, but it was not a true spatially resolved or organized patterning. The whole organoid became
one or another identity. For developmental studies, an imaginative, elegant, alternative to this situation was to
promote the fusion of differently patterned cerebroids, to study cell migration and the interconnections they could
develop when becoming physically in contact [12–14]. Obviously, this was an instrumental strategy to get different
regions (organoids) physically interacting, but distant from a truly spatially resolved patterning approach in a single
organoid.
Examples of diseases approached using the cerebroid technology
In spite of technical hurdles and reproducibility related difficulties inherent to the cerebroid model system,
researchers have successfully managed the study of the ethiology, as well as potential therapies, for diseases of high
personal and social impact and burden.
Most investigations have used brain organoids to model neurodevelopmental diseases like microcephaly [5,15],
autism [16,17], Rett syndrome [18], Miller-Dieker syndrome [19,20], schizophrenia [21], Sandhoff disease [22] or Zika
virus (ZIKV) infection involving neurodevelopment [9,15,23–27]. Also neurodegenerative diseases like Alzheimer’s
disease (AD) [28] and the potential for modeling Parkinson’s disease [11] were approached. Importantly, disorders
that manifest during embryonic/fetal development are more suitable for modeling in brain organoids, since brain
organoids, at the present stage, recreate particularly well the early brain development.
There are several methods available to obtain brain organoids recapitulating disease features. First, adult cells
(e.g., skin) can be taken from patients and reprogrammed into induced PSCs (iPSCs). Furthermore, it is possible
to introduce known mutations that are causally related of a disease into healthy cells. Also, in case of Zika virus for
example, a viral infection of the organoid is performed to study modifications induced by the disease. In parallel
to these disease models, organoids that were generated with healthy cell lines act as control for a comparison.
Recent studies are briefly summarized below to illustrate how brain organoids may be useful tools in the field of
neurological disorders.
In the case of microcephaly, Lancaster et al. were able to model some patterns of the disease. They observed
premature neuronal differentiation that caused a reduction of early progenitors and led to an overall reduced size of
the neuronal tissue compared with the (healthy) control organoids [29]. Gabriel et al. however, studied microcephaly,
which was induced by Zika viral infection [15]. They observed very similar manifestations, which strengthen the
reliability of modeling disease in brain organoids.
Several other studies investigated different strains of the Zika virus [9,15,23–27]. They all confirmed that a ZIKV
infected brain organoid has a reduced size similar to microcephaly and shows increased apoptosis. Moreover, Li et al.
highlight folding defects that were visible in ZIKV organoids [23], andQian et al. reported a decreased neuronal layer
thickness and an enlarged lumen [9]. Janssens et al. revealed that an African Zika strain modifies DNA methylation
in developing neurons by disturbing the activity of DNA methyltransferase [27]. Yoon et al. identified the NS2A
protein as responsible for reduced proliferation of radial glia cells in a Zika-infected brain by reducing adherens
junctions [26]. Dang et al. found out that Zika virus activates the Toll-like receptor 3, which is part of the innate
immune response, causing apoptosis and at the same time dysregulation of genes that steer neurogenesis, axon
guidance and differentiation [25]. Taken together, these studies emphasize the utility of brain organoids to reveal
new aspects of a human brain disease, which is the baseline on the way toward finding a therapy.
Mariani et al. studied glutamate neuron differentiation in brain organoids generated from cells of patients with
autism spectrum disorder (ASD) [16]. They found, that in ASD the FOXG1 gene is strongly expressed, which leads
to an overproduction of inhibitory neurons (GABA neurons). The amount of glutamate neurons however, was not
increased, which causes an imbalance between excitation and inhibition. Mariani et al. concluded that the FOXG1
gene is thus a molecular signature of ASD and could represent a future target in ASD therapy. Wang et al. produced
telencephalic organoids with a mutation in the CHD8 gene to study its impact in autism and schizophrenia [17].
They found thatCHD8 regulates the expression of the genes AUTS2 andTCF4 involved in ASD and schizophrenia,
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respectively. They highlight the possibility of identifying a drug target with the combined knowledge obtained
from their and other studies.
Stachowiak et al. modeled schizophrenia with cerebroids and investigated the role of FGFR1 [21]. The patient-
derived organoids showed a very different architecture compared with the control. Among others they displayed
an abnormal premature subcortical neurogenesis, which was apparent by a disruption of the developmental strata.
Ki67 positive (cycling) cells showed an increased proliferation by migrating from the ventricular zone into the
intermediate and cortical zone, which led to a reduction of mature neurons in the outer zone. They concluded that
these cells have failed to exit the cell cycle and consequently to differentiate. Due to this, the cortical neuronal cells
have a very low level of nuclear FGFR1, which is known to induce a dysregulation of downstream gene expression
crucial for neurogenesis. This would lead to cortical malformation during brain development of schizophrenia
patients. Stachowiak et al. state that changes in interneuron directionality could be the reason for disrupted cortical
interactions in schizophrenia [21]. Complementary, Ye et al. discovered with their patient-derived schizophrenia-
forebrain organoids (in parallel to in vivo studies), that a C-terminal mutation of DISC1 disrupts the interaction
withNdel1 [30]. They ascertained that this leads to a dysregulation of neuronal stem cell population in the ventricular
zone during forebrain development.
Raja et al. succeeded inmodeling disease patterns of Alzheimer’s – like amyloid aggregation, hyperphosphorylated
tau protein and endosome abnormalities in cerebral organoids. Also, they successfully tested the efficacy of β- and
γ-secretase inhibitors to reduce amyloid and tau pathology in Alzheimer patient-derived brain organoids [28]. Inter-
estingly, an alternative model did not use human PSCs, but a v-myc immortalized cell line of ventral mesencephalic
origin (ReNcell VM), to generate 3D tissue constructs for modeling AD [31].
A step toward modeling Parkinson’s disease in brain organoids was done by Monzel et al. [11] and Jo et al. [10],
who were able to generate brain organoids with midbrain identity, which contain not only dopaminergic neurons,
but also show electrophysiological activity and neuromelanin accumulation. It will be interesting in the future to
understand how dopaminergic neurons develop, and age, in Parkinson’s disease brain organoids.
All these studies show that brain organoids – even if the experimental model is far from being optimized –
have great potential for the study of some neurological diseases. Mostly, as described above, neurodevelopmental
conditions lead to a disease. However, the usefulness of cerebral organoids for neurodegenerative conditions
(e.g., AD, Parkinson’s disease and others) faces many challenges. As a main challenge stands the translation of
findings obtained in an in vitro system – cultured in vitro for many months – to reproduce the actual events
occurring during the progression of a chronic degenerative disease in the human brain. Nevertheless, two aspects
are of crucial importance: brain organoids from human PSCs provide the investigator with human tissues for
research, and their development in 3D, expected to better recreate human brain biology. Especially important will
be to exploit the use of brain organoids in the context of the 3Rs concept related to progressively reduce the use of
animals in research. Human cerebral tissue will accelerate and foster successful research into the actual molecular
and cellular key events leading to human disease, while reducing the unnecessary use of animals in research, a long
time awaited goal in neurobiology research.
Attempts to enhance reproducibility, & improving the experimental model
In order to develop improved cerebral organoids for neurobiology/neurological research, it needs to be solved
how to prospectively, provide spatially resolved regional patterning and specification cues in a whole cerebroid.
Optimally, neurological research needs of cerebroids in which discrete brain regions could be prospectively generated
at desired spatial locations being meaningfully organized, spatially resolved, to study for instance how projection
and communication between different developing regions are established, modulated, remodeled, and how they
survive and degenerate.
One of the possible solutions to this hurdle will be to engineer scaffolds with biocompatible materials for the
development of cerebroids with improved organization. Such scaffold should provide perfusion/vascularization, as
well as spatially distinct developmental cues, and overall, allow for the development of a self-organizing cerebroid.
Optimally, such scaffold should also have electrically conducting properties for the stimulation and monitoring
(bio-sensing) of the developing cells.
Next, the use of genuine (self-organized, nonpatterned) cerebral organoids as a model system for any type of
systematic study, is hampered from a very low reproducibility rate. As described above, the generation of neural
tissue in a cerebral organoid occurs stochastically. Moreover, the different neuronal types in the same organoid
are generated almost randomly and most importantly, without control by the investigator. However, since the
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development of an organoid resides in the self-organization and self-development capacities of the tissue, any
interference with the ‘self-drive’ may result in an impaired development of the organoid, a difficulty that should be
carefully considered.
While recognizing the interest of bulk-patterned organoids (very similar to patterned neurospheres) for some
limited studies, the ideal scenario would be to generate an organoid with prospectively generated brain region
identities at different locations, and that will show some type of communication/projection between different
brain regions, spatially separated. For instance, to study cortico-striatal or nigro-striatal projections, and many
others.
Basic requirements would be to enlarge the tissue constructs; to provide the developing organoid with a
supportive (perfusable) scaffold, which would both provide physical and physiological support, and; providing
spatially separated, regional developmental cues, for instance by hydrogels deposited at different locations in the
scaffolds, loaded with different developmental cue molecules.
Research in this line includes attempts to provide the organoids with vascularization [32,33] and blood–brain
barrier [34] in various ways. We expect seeing exciting developments in these research lines, which will help to
exploit the full potential of cerebral organoids.
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